PPCB · Propanc Biopharma, Inc. · Documents

Jun 5

Current report 8-K Events of May 31

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

May 16

Current report 8-K Events of May 10

Entered into a material agreement, New debt or off-balance-sheet obligation

May 15

Quarterly report 10-Q FY2024 Q3, ended Mar 31

Quarterly report for FY2024 Q3

Net loss $526.7K Diluted EPS -$0.01

Apr 22

Current report 8-K Events of Apr 16

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Apr 10

Current report 8-K

Other events

Mar 11

Current report 8-K Events of Mar 5

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Feb 20

Quarterly report 10-Q FY2024 Q2, ended Dec 31

Quarterly report for FY2024 Q2

Net loss $584.38K Diluted EPS -$0.03

Feb 14

Late filing notice NT 10-Q

Late filing notice

Dec 15

Current report 8-K Events of Dec 11

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Dec 7

Current report 8-K Events of Dec 4

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Nov 14

Quarterly report 10-Q FY2024 Q1, ended Sep 30

Quarterly report for FY2024 Q1

Net loss $350.87K Diluted EPS -$0.04

Oct 30

Current report 8-K Events of Oct 29

Other events

Oct 26

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Oct 17

Current report 8-K Events of Oct 16

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Oct 10

Registration statement S-1/A

Registration statement

Oct 6

Registration statement S-1/A

Registration statement

Sep 28

Annual report 10-K FY2023, ended Jun 30

Annual report for FY2023

Net loss $2.66M Diluted EPS -$1.80

Aug 29

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Aug 21

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Aug 11

Registration statement S-1

Registration statement

Aug 8

Current report 8-K

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Jul 26

Current report 8-K

Entered into a material agreement, Unregistered sale of equity

Jul 12

Current report 8-K Events of Jun 29

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

May 15

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Debt obligation accelerated or increased, Unregistered sale of equity

May 15

Quarterly report 10-Q FY2023 Q3, ended Mar 31

Quarterly report for FY2023 Q3

Net loss $809.81K

May 5

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Mar 17

Current report 8-K Events of Mar 15

Charter or bylaw amendment, or fiscal year change

Feb 22

Current report 8-K Events of Feb 15

Other events

Feb 21

Current report 8-K Events of Feb 14

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Feb 10

Quarterly report 10-Q FY2023 Q2, ended Dec 31

Quarterly report for FY2023 Q2

Net loss $485.42K

Nov 14

Quarterly report 10-Q FY2023 Q1, ended Sep 30

Quarterly report for FY2023 Q1

Net loss $617.3K

Nov 1

Current report 8-K Events of Oct 26

Director or officer change, or executive pay

Oct 12

Current report 8-K Events of Oct 6

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Sep 28

Annual report 10-K FY2022, ended Jun 30

Annual report for FY2022

Net loss $2.66M

Sep 27

Current report 8-K Events of Sep 21

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Aug 18

Current report 8-K Events of Aug 12

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Jul 11

Current report 8-K Events of Jul 6

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Jul 7

Current report 8-K Events of Jun 30

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

May 18

Current report 8-K Events of May 12

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

May 16

Quarterly report 10-Q FY2022 Q3, ended Mar 31

Quarterly report for FY2022 Q3

Net loss $462.69K

Apr 18

Current report 8-K Events of Apr 12

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Apr 1

Current report 8-K Events of Mar 29

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Mar 10

Current report 8-K Events of Mar 7

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Feb 14

Quarterly report 10-Q FY2022 Q2, ended Dec 31

Quarterly report for FY2022 Q2

Net loss $799.98K

Feb 10

Registration statement S-1/A

Registration statement

Feb 3

Registration statement S-1

Registration statement

Jan 10

Current report 8-K Events of Jan 4

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Dec 13

Current report 8-K Events of Dec 7

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Dec 7

Current report 8-K Events of Nov 30

Entered into a material agreement, Unregistered sale of equity

Dec 1

Current report 8-K Events of Nov 26

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity